Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-08-20

Clinical Trial Update: Memantine for Refractory OCD Patients [Phase 3]

View source ↗

Summary

Phase 3 clinical trial investigating memantine for refractory obsessive-compulsive disorder is reported as ongoing with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Memantine (memantine)

Snippet

Sponsor: University of Roma La Sapienza | Conditions: Obsessive-Compulsive Disorder | Phase 3 | Status: UNKNOWN